SightfileU.S. market data from official filings

METAGENOMI THERAPEUTICS INC (MGX)

Name: METAGENOMI THERAPEUTICS INC (MGX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001785279 · EDGAR filings · Updated 2026-06-11

METAGENOMI THERAPEUTICS INC (MGX) has reported institutional ownership of 17.2%, with 48 institutional managers holding positions valued at $8.65M per the latest 13F reporting period.

Institutional ownership

17.2%

Institutional managers

Reported 13F value

$8.65M

Insider activity

27 trans.

−$72.0K net selling

Latest updates

2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-10 — Insider transaction reported (Form 4)
2026-06-10 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, METAGENOMI THERAPEUTICS INC has 48 institutional holders and institutional ownership of 17.2%.

Insider activity

Insiders reported 27 transactions (0 buys, 16 sells) across 5 reporting insiders, with a net reported value of −$72.0K.

Related companies

CITIUS ONCOLOGY INC COM (CTOR) · Entera Bio Ltd (ENTX) · IMMUCELL CORP (ICCC) · MYOMO INC (MYO) · Curis Inc (CRIS) · TVARDI THERAPEUTICS INC COM (TVRD)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-11.